Results:
Median age was 68 years (range 56-76). DP are presented in table 1. In 33/40 implants in pts with EBRT+HDR-BT dose-escalation to the PZ was reached (range 6 -44% of the prescribed dose). The median V100 for the prostate was 94.5% (CI ±1.6%). in 26/30 of the implants in pts with HDR-BT monotherapy the intended dose-escalation was reached (range 6 -40% of the prescribed dose). The median V100 for the prostate was 92.8% (CI ±2.2%). No grade ≥3 toxicity was observed. Grade 2 toxicity was 13% and resolved within 1 month in 90% of the pts.
Conclusion: HDR-BT with SIB to the PZ is feasible in both combined and monotherapy settings. Acute toxicity was mild. Local control and late toxicity profile should be investigated prospectively. Purpose or Objective: This prospective longitudinal study quantifies patient reported Quality of Life (QoL) pretreatment and up to ten years following permanent I-125 prostate brachytherapy delivered as monotherapy in a single institution Material and Methods: 120 patients were asked to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire, a comprehensive validated QoL tool designed to evaluate patient function and bother after prostate cancer treatment. Men completed the EPIC questionnaire before brachytherapy and at 8 time points after treatment (6 weeks; 6,10 and 18 months; 2,3,5, and 10 years). At each time point clinically relevant small, moderate and severe declines in QoL were defined as 0.2-0.5 times SD, 0.5-0.8 times SD and > 0.8 times SD of baseline function for each of urinary, bowel and sexual domains respectively.
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Results:
Response rates in the first two years were >90% but thereafter dropped to 75% at 5 years and 48% at 10 years. 50 patients (41.6%) responded at all stages. Maximal deterioration in mean urinary and sexual summary scores was noted 6 weeks after implant with severe urinary symptoms and moderate bowel/sexual symptoms at that point. At 6 months urinary and bowel QoL had improved to mild impairment which then fully resolved by 10 months. Sexual QoL remained mildly impaired throughout the 10 years. At 10 years new mild impairment of urinary and bowel QoL was also found.
Conclusion: Clinically mild changes in urinary, bowel and sexual QoL are found 10 years after I-125 monotherapy. The impairment in sexual function persists from treatment but urinary and bowel symptoms are new at 10 years and may be either a late effect of brachytherapy or due to increasing age. BARD) . For each group we calculate the mean D90 in the "postplanning" (evaluated on CT images after 60 days) and the difference between planning and postplanning in terms of D90 and V100 (dose fall-off). In the last group we evaluate also the difference, in terms of D90, V100 and maximum urethra dose between the theoretical planning and the effective implant, evaluated in the operating room on the ultrasound images at the end of the surgery.
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ESTRO 35 2016 ______________________________________________________________________________________________________ Results: Results: in the 4 groups the results in terms of D90 are respectively 123±32Gy, 146±28Gy, 153±23Gy, 166±17Gy, as shown in Figure 1 . The dose fall-off in terms of D90 is respectively 58Gy, 43Gy, 37Gy, 21Gy (as shown in Figure 2 ) and in terms of V100 17%, 10%, 8%, 4%. In the last group the mean theoretical D90 and V100 are 187Gy and 99%, against a real implant evaluation of 186Gy and 99%and the maximum urethra dose is 210Gy in the planning and 219Gy at the end of the implant. In the 30% of the patients of the "real-time" group we changed the number of seeds or needles composition during the implant, to reach the desired constraints and PTV coverage.
Conclusion:
Conclusion: our work shows the impact of the "image-guided" technology evolution on the dose fall-off both in terms of D90 and V100. Moreover, we show how the "real-time" method allows to change the "theoretical" plan during the implant, to reach the recommended constraints and PTV coverage [1]. (Brachytherapy, 2009) , which highlighted our methodology of limiting needle trauma, relying on Intra-operative, Real-Time computer assisted IO (Inverse Optimization) to reduce the number of sources and total activity without compromising dosimetric quality. This update was performed to confirm our earlier favorable BFFS outcomes.
PO-0979 LTB control and toxicity for Favorable and Intmed Risk pts using real time IO-PSI prostate BT alone
Material and Methods:
Between 2001 and 2013, 491 patients underwent real-time IO-PSI. Only patients with a minimum of 2 years of follow-up treated without supplemental IMRT were the subject of this analysis (N=315). Our dose objectives and constraints for real-time IO-PSI have previously been published and remain unchanged. The main dose objective intra-operatively was to achieve a V100 > 95% (Volume receiving > 95% of the prescribed dose). Patients were implanted with either 125 I (PD=145 Gy) or 103 Pd (PD =120 Gy). Toxicity was prospectively scored using the Radiation Oncology Group Toxicity scale and the International Prostate Symptom Score questionnaire. Biochemical control was determined using the nadir+2 ng/ml definition.
Results:
The mean and median followup was 58 and 54 months respectively (range: 24-110 months). The NCCN risk classification for FR and IR patients were used. 125 I sources were used for 93% of the implants, and 103 Pd for 7%. 89% of patients presented with FR disease while 10% presented with IR, and in 2 cases HR. (1%). The median number of sources and total activity implanted were 65 and 999MBq, respectively. The median prostate volume implanted was 36 cc. The median V100 was 95%. Absolute BNED was 97%. The 10 year actuarial probability of biochemical control rate for all patients was 95%, with no difference observed between FR or IR patients (97% and 95% respectively) Late Gu and GI Grade 2 and higher toxicity was very low. With a minimum follow-up for 2 years, the late Grade 2 and Grade 3 GU toxicity was 19% and 1% respectively. The late Grade 2 and 3 rectal bleeding rate was 1% and 0% respectively, with no Grade 4 toxicity observed.
